ABSTRACT BCG is the collective name for a family of live attenuated strains of Mycobacterium bovis that are currently used as the only vaccine against tuberculosis (TB). There are two major reasons for studying the genome of these organisms: (i) Because they are attenuated, BCG vaccines provide a window into Mycobacterium tuberculosis virulence, and (ii) because they have provided protection in several clinical trials and case-control studies, BCG vaccines may shed light on properties required of a TB vaccine. Since the determination of the M. tuberculosis genome in 1998, the study of BCG vaccines has accelerated dramatically, offering data on the genomic differences between virulent M. tuberculosis, M. bovis, and the vaccine strains. While these findings have been rewarding for the study of virulence, there is unfortunately less accrued knowledge about protection. In this chapter, we review briefly the history of BCG vaccines and then touch upon studies over the past two decades that help explain how BCG underwent attenuation, concluding with some more speculative comments as to how these vaccines might offer protection against TB.
HISTORY OF BCG SUBSTRAINS
BCG is named for Albert Calmette and Camille Guérin (bacillus of Calmette and Guérin) , who derived the original strain between 1908 and 1921 at the Institut Pasteur of Lille. By serially passaging Nocard's strain of M. bovis on potato slices soaked in ox bile and glycerol, they observed a gradual loss of its ability to cause disease in various animal models (1, 2) , leading finally to the attempt to use it as a vaccine for the prevention of tuberculosis (TB) in humans in 1921 (reviewed in reference 3).
After Calmette and Guérin proved BCG to be attenuated and safe, cultures of BCG strains were sent out from the Institut Pasteur to different laboratories throughout the world starting from 1924; these cultures were further propagated and used for vaccine production. Lyophilization of vaccine lots became available in the latter half of the 20th century, exposing different BCG daughter strains to some 1,000 additional passages of in vitro evolution in different laboratories. This means that BCG does not refer to a cloned strain but rather to a family of different BCG seed strains ("substrains") used in BCG manufacture that have acquired particular genomic modifications during passaging in the various laboratories.
Investigation of the records of BCG transfers between laboratories has enabled the reconstruction of the history of the different BCG daughter strains. Although BCG vaccines have been produced in a wide variety of countries (e.g., Australia, Bulgaria, Mexico, Romania, etc.), for the purpose of genetic studies of BCG strains, a representative subset is generally selected, based on strains used in clinical trials or currently in wide use in vaccination programs. Reviews of the history of these strains have been published by different groups and showed agreement of the proposed provenance of these strains (4, 5) . The natural historical division that arises from these genealogic trees is the separation of "early strains" obtained in the early 1920s (BCG Russia, BCG Brazil, BCG Tokyo, BCG Sweden, BCG Birkhaug) from "late strains" obtained from the Pasteur Institute in 1927 or later (outlined in Fig. 1 ). The distinction between early strains and late strains coincides with reports of ongoing attenuation of BCG in the late 1920s (6, 7) and is correlated with severely reduced production of the antigenic proteins MPB70, MPB83, and MPB64 in late strains (8) . However, whether this historical distinction is critical for BCG phenotypes remains uncertain, because certain properties, such as production of virulence lipids, have been independently lost in both early and late strains. Moreover, the relevance of an early versus late dichotomy in terms of protective efficacy in humans cannot be ascertained, because randomized clinical trials of BCG vaccination only employed late strains.
Since 1921, an estimated 4 billion doses of BCG have been administered worldwide with remarkably low incidence of major side effects in immune-competent individuals. One survey conducted in France estimated that the rate of BCG-osis is on the order of 1 per million vaccinees, although allowing for under-diagnosis and/or under-reporting, it is possible that the risk is somewhat higher (9) . Still, this attack rate remains orders of magnitude lower than that of virulent M. tuberculosis, where the widely reported risk of progression from documented infection to disease is about 10% over one's lifetime. Therefore, it is worth reflecting that despite great similarities in genomes between virulent M. tuberculosis and BCG, the genomic differences translate into a 4-to 5-log lower risk of disease. These epidemiologic data, compiled over decades in countries worldwide, provide a compelling argument for using BCG as an entrée to study attenuation of virulence during laboratory passage.
In contrast to the indisputable evidence of attenuation, the data on protective efficacy are somewhat more controversial. BCG vaccination is felt to be effective against disseminated forms of TB in children (80%), such as miliary TB and meningitis (10, 11) , although the data supporting this protection are derived mostly from observational and case-control studies. In randomized controlled trials, BCG vaccination has provided as much as 80% protection in several studies (12, 13) but fared no better than placebo in others (14, 15) , leading to a policy stalemate, where findings from either pole of the efficacy spectrum have been used to justify national immunization guidelines. Adding further confusion, BCG vaccination has also been shown to protect against leprosy in a controlled trial where it did not protect against TB (16) . A wide range of BCG schedules have emerged (17) , tabulated at the BCG Atlas (http://www .bcgatlas.org/). In countries with low or declining rates of TB, BCG vaccination has either never been used or has been stopped in recent decades. In most other parts of the world, routine BCG vaccination is applied either to all subjects or only in high-risk communities, with schedules that can be divided into three groups: BCG administration only at birth, BCG once in childhood,or repeated/booster BCG. It has been estimated that over 100 million doses of BCG are administered each year (18) . Although vaccines more effective than BCG are needed, BCG vaccination will probably continue for at least the next decade on a worldwide scale until controlled long-term vaccine trials prove that novel anti-TB vaccines offer better protection. Moreover, of novel vaccines in development, candidates that have performed better than BCG in animal models have been modified forms of BCG vaccines (19) (20) (21) . As such, molecular and immunological characterization of the currently used BCG vaccine strains continues to be an important research topic, not only to elucidate the genetic basis for the attenuation of BCG, but also to learn more about the genetic background of diverse BCG substrains that may serve as the backbone of new vaccines. Recent advances in the field of mycobacterial genetics, comparative genomics, and related techniques have supplied an enormous amount of new information, which will be summarized and discussed in this chapter.
BCG AS AN ATTENUATED MEMBER OF THE M. TUBERCULOSIS COMPLEX
M. bovis BCG emerged as an attenuated mutant of M. bovis. Thus, comparisons between M. tuberculosis and BCG will naturally present two strata of differences: M. tuberculosis versus M. bovis and M. bovis versus BCG. While it is tempting to disregard other naturally occurring variants of the tubercle bacillus, some surprising observations have been made upon genomic study of organisms such as Mycobacterium microti (Voles bacillus), Mycobacterium mungi (TB in mongooses) and the dassie bacillus (TB in hyraxes). In common with BCG vaccines, these other three subspecies of the M. tuberculosis complex are deletion mutants in the region of difference 1 (RD1) locus of the genome (22) (23) (24) , and consequently each of these organisms lacks a functional ESX-1 secretion system (discussed in greater detail in reference 73). One interpretation of this observation is that the lack of ESX-1 in these organisms explains why they are apparently attenuated for humans. Indeed, we rarely see human TB due to these organisms, and M. microti has even been used, with an excellent safety record, in field trials of TB vaccination (13) . A further inference is that these organisms are able to cause transmissible disease in their natural hosts without ESX-1. This suggests that either alternative virulence mechanisms have emerged to make up for this defect or that permissive host factors have enabled the propagation of attenuated variants of the tubercle bacillus. In either case, these natural experiments serve to remind us that M. tuberculosis virulence depends on more than the presence of ESX-1, such that this locus is perhaps best deemed necessary but not sufficient for full virulence.
Setting aside other members of the M. tuberculosis complex, postgenomic study has affirmed that BCG did indeed derive from M. bovis, itself comprising at least four different genotypes (25) . Since the original strain of M. bovis used to derive BCG was lost during the First World War, genomic studies have compared BCG vaccines to a variety of different M. bovis strains until the sequencing of the AF2122/97 strain was completed in 2003 (26) . As a consequence, it must be remembered that certain differences uncovered between a particular BCG strain and the chosen M. bovis strain could represent M. bovis-M. bovis variants rather than BCGspecific differences. Fortunately, the existence of a variety of contemporary BCG strains provides opportunities to logically deduce the genetics of the original BCG. For instance, BCG strains obtained before 1926 (BCG Russia, BCG Moreau, and BCG Tokyo) all have an IS6110 element at base pair 851,592 of the H37Rv genome, unlike other BCG strains, where the sequence at this locus is identical to that of M. tuberculosis and M. bovis (27) . One reason why it is much more likely that the original BCG strain contained this second IS element is that the alternative (and unlikely) event would be that, on three different continents, a transpositional duplication of IS6110 occurred at precisely the same locus.
Therefore, based on the availability of a number of different BCG strains, and the genomic sequences of M. tuberculosis H37Rv and M. bovis AF2122/97, it is now possible to describe the genomic evolution of BCG strains in various vaccine laboratories. In the section below we will document what is currently known from such studies about the genome of BCG strains, recognizing that the overriding challenge is not to find genetic differences between strains, but rather to use these data to answer biologic questions, such as (i) why are BCG vaccines attenuated?, (ii) are some strains overattenuated?, and (ii) what are the properties of BCG that offer protection against TB?
MOLECULAR EVOLUTION AND THE DERIVATION OF BCG SUBSTRAINS
As described above, BCG is not a clonal organism, and several substrains exist that may have accumulated individual genetic modifications due to long-term passaging in different laboratories and vaccine production facilities. Using the historical records about when and where BCG strains were distributed, together with information on the genetic particularities of certain BCG ASMscience.org/MicrobiolSpectrumsubstrains, the short-term evolution of BCG strains can be reconstructed. By employing techniques of comparative genome analyses, such as subtractive hybridization, BAC libraries, microarrays, and GeneChips, it was shown that several BCG daughter strains indeed have accumulated additional genomic modifications that apparently were not present in the original culture obtained by Calmette and Guérin (27) (28) (29) (30) (31) . With the huge amount of genomic data that have been generated in the last few years, including NimbleGen resequencing arrays and whole-genome sequencing, the previously reported genealogy of BCG strains has been retained, with smaller polymorphisms uncovered, specific to each strain. At last count, there are 27 BCG genome sequences deposited at NCBI (search performed July 2013), indicating that all of the most commonly used strains of BCG have been subject to whole-genome sequencing.
Based on the available data, it is now clear which genetic particularities are shared across all BCG strains relative to other M. bovis strains and which genetic variations are specific for only certain BCG substrains. Whereas the former may be directly involved in the attenuation of BCG, the latter may account for variation in protective efficacy and/or overattenuation of certain BCG substrains. For the genomic particularities that apply to all BCG substrains and are shown to be implicated in virulence, the example of the RD1 region will be discussed separately below. The variations that were observed for only certain substrains of BCG consist of deletions, duplications, and point mutations. Of note, deletions were discovered about one decade before most point mutations, simply because it is easier to find large chunks of missing DNA than single base-pair substitutions. As a result, there has been more time to pursue functional studies of the deletions than of single nucleotide polymorphisms (SNPs), with an ensuing bias in the kinds of mutations that have been linked to phenotypic consequences.
Among the genomic deletions specific to BCG vaccines, without question the one that has attracted the most attention is the RD1, first identified by subtractive hybridization between BCG and wild-type M. bovis (28) . When preliminary complementation experiments of BCG with the RD1 from M. bovis did not result in increased virulence of the recombinant BCG strain in mice (28) , the hypothesis that RD1 could be involved in the attenuation of BCG remained unconfirmed for several years. Yet several years later, RD1 remained the only genomic deletion specific to BCG (29, 30) , prompting three independent teams of investigators to revisit the potential role of RD1 loss in the attenuation of BCG. In one study, BCG Pasteur was complemented with an integrative cosmid clone containing the RD1, and the recombinant BCG strain was more virulent in severe combined immune deficient (SCID) mice than the BCG-vector control strain (22) . In the other two studies, RD1 was disrupted from M. tuberculosis, with both groups reporting decreased virulence of M. tuberculosis ΔRD1 compared to the reference strain of M. tuberculosis (32, 33) . Together, these data implicated RD1 deletion as a key mechanism of BCG attenuation; however, they did not exclude other mutations as also contributing to the loss of virulence described by Guérin between 1908 and 1921 .
In addition to RD1, several other genomic polymorphisms that are common to all BCG strains have been investigated, including several point mutations that may have contributed to the early evolution of BCG. One example is a SNP in pykA, which encodes pyruvate kinase, an enzyme that catalyzes the final step in glycolysis. This point mutation results in an aspartic acid substitution at glutamic acid 220 and renders pyruvate kinase nonfunctional. Interestingly, this SNP is present in M. bovis but absent in BCG and was suggested to account for the inability of M. bovis to grow on glycerol as a sole carbon source (34) . Since all the BCG strains that were tested exhibited functional pyruvate kinase enzyme activity, it was suggested that the original growth conditions (i.e., potato slices soaked in ox bile and glycerol) used in the in vitro passaging of M. bovis by Calmette and Guérin had selected for a strain of M. bovis capable of utilizing glycerol.
Another study implicated a point mutation in the gene that encodes the cyclic AMP (cAMP) receptor protein (CRP) (Rv3676) in BCG that could affect the DNA binding activity of this putative global transcriptional regulator and thus contribute to BCG attenuation (35) . Follow-up studies using electrophoretic mobility shift assays (EMSA), chromatin immunoprecipitation (ChIP), and DNA microarrays coupled with quantitative reverse transcription PCR (qRT-PCR) showed that the point mutation resulting in a glutamic acid-to-lysine substitution (E178K) present in all BCG strains tested increased DNA binding of CRP to target sites and increased expression of targets (36, 37) . However, it was shown that CRP from BCG was able to rescue the growth defect of a CRP mutant of M. tuberculosis in macrophages and BALB/c mice, suggesting that this SNP does not necessarily contribute to BCG attenuation. Rather, this SNP may have merely conferred a survival advantage for BCG under the in vitro conditions used in the initial derivation by Calmette and Guérin (37) .
A recent comprehensive study of SNPs between M. bovis and BCG strains uncovered additional point mutations that could also play a role in the early evolution of BCG (38) . Two follow-up studies examined these SNPs in BCG. The first examined a SNP found in BCG3145, an ortholog of Rv3124 in M. tuberculosis. BCG3145/Rv3124 are members of the AfsR/DnrI/SARP (Streptomyces antibiotic regulatory protein) class of transcriptional regulators and, by microarray and qRT-PCR analysis, were found to positively regulate the mao1 locus required for molybdopterin biosynthesis (39) . Interestingly, the E159G (glutamic acid-to-glycine substitution) mutation in BCG3145 caused a reduction in activity but did not abolish induction of the moa1 locus. Given that Rv3124 has not been identified as a virulence factor for M. tuberculosis, these authors suggested that this mutation is likely not a key attenuating genetic lesion in BCG, but this has not been formally tested. The second study examined a nonsynonymous SNP in cycA, which encodes a D-serine/D,L-alanine/glycine/D-cycloserine transporter. This study showed that the G122S (glycineto-serine substitution) in cycA was responsible for the D-cycloserine resistance seen in BCG strains. Interestingly, expression of a functional copy of cycA from M. tuberculosis or M. bovis increased susceptibility of BCG Pasteur to D-cycloserine, albeit not to the levels of M. tuberculosis or M. bovis, suggesting that other genetic lesions may contribute to BCG resistance to d-cycloserine (40) . Whether this mutation has a functional consequence on BCG virulence remains unknown. Although these SNPs have not been directly implicated in the original attenuation of BCG, it remains possible that the accumulation of multiple SNPs between 1908 and 1921 may have resulted in a compound effect that is difficult to formally prove by piecemeal study.
MOLECULAR EVOLUTION AND THE PROPAGATION OF BCG SUBSTRAINS
Subsequent to the original derivation of BCG, strains were passaged in nonsynthetic media, based on variable growth factors such as the local potatoes obtained at one's farmer's market. Not surprisingly, these laboratory conditions were not uniform, and it was perhaps not surprising that BCG laboratories noticed phenotypic differences between their strains in the 1940s and 1950s. With genomic study, it is now known that different BCG strains differ both from the original BCG of 1921 and from each other, due to deletions, SNPs, and duplications. Thus, there is no "ancestral" BCG in existence. BCG Russia may look more ancestral than BCG Pasteur, because the latter is separated from BCG 1921 by a number of genetic events (e.g., deletion of IS6110, RD2, nRD18, and RD14; SNPs in mmaA3, sigK, and CRP; duplication of DU1) (Fig. 2) . However, BCG Russia is expected to harbor a number of mutations compared to BCG 1921 that are not observed in BCG Pasteur. Evidence to suggest a closer relationship between BCG Russia and the original BCG progenitor strain has emerged from the discovery that BCG Russia is a natural recA mutant (41) . This mutation was suggested to have prevented BCG Russia from undergoing further genetic evolution, but whether this occurred soon after the strain arrived in Russia or decades later cannot be determined.
Since the deletion of RD1 coincided with and contributed to the attenuation of virulence, it has been tempting to hypothesize that other deletions have contributed to further attenuation. Of genes contained in BCG deletions, a number stand out as candidates for the ongoing attenuation of BCG strains in the laboratory. The RD2 region, encompassing Rv1978 to Rv1988, has been disrupted from M. tuberculosis, and the deletion mutant was shown to be attenuated in murine models of infection (42) . Moreover, the RD2 region contains the gene mpt64, coding for the antigenic protein MPT64; introduction of mpt64 into BCG Pasteur improved the immunogenicity of the vaccine strain without providing a protection benefit (43) . Rv3405c, annotated as a possible transcriptional regulator, has been disrupted by independent deletions in two different BCG strains (see below). Two other predicted regulators have been disrupted during serial passage of BCG strains. Rv1773, also annotated as a probable transcriptional regulatory protein, has been deleted from the BCG Pasteur strain alone (29) ; its regulatory role was subsequently confirmed (44). Finally, Rv1189, otherwise known as sigI (possible alternative RNA polymerase sigma factor SigI), is missing from all BCG strains obtained after 1933. The loss of regulatory genes from a number of different BCG strains argues that mutation of regulatory genes can be tolerated during the monotonous conditions of laboratory growth.
Three BCG strains (BCG Japan, BCG Glaxo, and BCG Moreau) were found to be naturally deficient in lipid virulence factors, phthiocerol dimycocerosates (PDIMs), and phenolic glycolipids (PGLs). The loss of these lipids correlates with the superior safety records of these strains in clinical studies (45, 46) . Furthermore, deletion of PDIMs/PGLs from BCG Pasteur reduces its virulence in SCID mice (V. Tran et al., unpublished data). Genomic analysis revealed that the loss of PDIMs/ PGLs in BCG Moreau is due to a 975-bp deletion that affects fadD26 and ppsA, members of the PDIM/PGL biosynthetic operon (47) . Similarly, a point mutation in ppsA is responsible for the lack of PDIMs/PGLs in BCG Japan (48) . The mutation in BCG Glaxo has yet to be discovered. Together, this suggests that these three BCG strains independently acquired mutations in PDIM/PGL biosynthesis that contributed to their further attenuation. Several BCG strains harbor mutations in the phoPphoR locus, a two-component system known to regulate the expression of multiple genes, including some well-established T-cell antigens (49) . Of note, a frameshift mutation present in phoP of BCG Prague eliminates the C-terminal binding domain and makes this strain a natural phoP mutant (47) . It is possible that this could account for this strain's reported low immunogenicity (50, 51) . In addition, as mentioned above, three early BCG strains have an IS6110 insertion in the phoP promoter, which could eliminate the auto-repression regulatory mechanism of this two-component system (52) , and five BCG strains contain mutations in the phoR gene that may abrogate its function. Unlike other BCG strains, BCG Sweden and BCG Birkhaug also contain mutations in whiB3, a transcriptional regulator FIGURE 2 Evolutionary scheme of BCG after its genome sequencing (from reference 58), indicating that M. bovis BCG has undergone deletions, duplications, and SNPs since its divergence from M. bovis. doi:10.1128/microbiolspec.MGM2-0028-2013.f2 implicated in virulence of M. bovis (53) and M. tuberculosis (54), and in trcR, the response regulator of the TrcR-TrcS two-component system that controls expression of the trcRS operon, including mmpS5/mmpL5 transporter and bfrB bacteroferritin (55) . Interestingly, deletion of trcS from M. tuberculosis produced a hypervirulent phenotype in SCID mice (56) , which suggests a role for this gene in the attenuation of BCG.
Comparative genomics has also uncovered two large tandem duplications of 29 and 36 kb (DU1, DU2) in BCG Pasteur (57, 58). These seem to have arisen independently, as their presence and/or their size varies between the different BCG substrains. While DU1 appears to be restricted to BCG Pasteur, DU2 has been detected in all BCG substrains tested so far (58). Interestingly, DU1 comprises the oriC locus, indicating that BCG Pasteur is diploid for oriC, and several genes involved in replication (57). For DU2, we know that the tandem duplication resulted in diploidy for 30 genes, including sigH, a sigma factor implicated in the heat shock response (59) . Gene duplications are a common evolutionary response in bacteria exposed to different selection pressures in the laboratory and presumably in nature, because they provide a means for increasing gene dosage and for generating novel functions from potential gene fusion events at duplication endpoints, and they represent a source of redundant DNA for divergence. As such, the duplication events seen in BCG Pasteur may reflect a common adaptation mechanism of mycobacteria to cope with environmental stress, and they could influence the immunogenicity of a certain vaccine strain. Other duplications specific to certain BCG strains have also been uncovered, such as a 22-kb duplication present only in BCG Tice (DU-Tice) (47) . This duplication encompasses Rv1782-Rv1800 that encodes the ESX-5 secretion system, which is present only in pathogenic mycobacteria and has been shown to facilitate the cell-to-cell spread of Mycobacterium marinum in infected macrophages, a function shared by ESX-1 (60) .
The search for BCG-associated SNPs has occurred in two waves: phenotype to genotype and, more recently, from whole-genome sequencing. Two examples of phenotype-driven searches involve the variable production of lipids by BCG strains. In the first example, it had been known since the 1980s that production of mycolic acid subsets varied across BCG strains (61) . Since the gene mmaA3 had been shown to be involved in production of methoxymycolic acids (62) , it was hypothesized that mutations in this gene might explain this variable phenotype. Indeed, methoxymycolic acid production is restricted to "early strains," and "late strains" all have a guanine-to-adenine replacement at base pair 293 of the mmaA3 gene (63) . By introducing this mutant form of mmaA3 into M. smegmatis, it was possible to verify that ablation of methoxymycolate synthesis occurs with this mutation. Additionally, in a follow-up study, the wild-type sequence of mmaA3 was complemented into two late strains, BCG Danish and BCG Pasteur, with restoration of methoxymycolate synthesis (64) . The second example of such a phenotype-to-genotype search was provided above, in the case of PDIMs and PGLs.
In contrast, the higher throughput means of identifying BCG-specific mutations involves whole-genome sequencing. Prior to the complete closure and annotation of BCG Pasteur in 2007 (58), the shotgun reads available on the Internet helped frame the search for a genetic basis to a transcriptome difference that separated early from late strains. During in vitro growth, it was noted that the genes mpt70 and mpt83 were differentially expressed in early strains, consistent with the previously published difference in expression of the antigenic proteins that they encode (MPT70, MPT83). The same strains with high expression of these genes had overexpression of a set of genes from Rv0449c to Rv0444c, a run of genes that includes the gene sigK, coding for the extracytosolic sigma factor SigK. By alignment of the sigK sequences, it was seen that BCG Pasteur had a start codon polymorphism, prompting targeted sequencing of sigK across BCG strains. Because this mutation correlated with the strains obtained in 1931 or later, the wild-type sigK was introduced into BCG Pasteur, restoring expression of mpt70/mpt83 and production of MPT70/MPT83 (65) . While the restoration of the wild-type expression profile led to clear differences in immunogenicity of BCG Pasteur, as measured by MPT70-specific interferon-γ production by vaccinated animals, there was no benefit in terms of protective efficacy, in both guinea pigs and calves (M. A. Behr, unpublished data). These findings once again highlight how the documentation of genetic changes among BCG strains has far outstripped our capacity to define the basis of protective efficacy.
Following the sequencing of BCG Pasteur in 2007 and publication of the BCG Pasteur genome, the sequencing of BCG Tokyo was determined in 2009, aiding in the search for further differences between early and late BCG strains (66) . The sequencing of four additional BCG strains (BCG Russia, BCG Tice, BCG Denmark 1331, and BCG China) uncovered more than 360 SNPs between these BCG strains compared to M. bovis (67) . Of these, ∼170 SNPs were unique to BCG, and some were exclusive to specific strains, which may have contributed to the evolution of each strain. Wholegenome sequencing of BCG Moreau confirmed the presence of several genetic aberrations including DU2-1, fadD26-ppsA 976 bp deletion, RD16 deletion, and inframe deletion in the rv3887c (eccD2) gene (68) . Interestingly, sequencing of BCG Mexico 1931 repositioned this strain from the DU2-III group into the DU2-IV group that includes BCG Pasteur, BCG Connaught, BCG Tice, BCG Frappier, and BCG Phipps. This analysis revealed that BCG Mexico was not originally derived from BCG Danish, as previously thought, and that this inconsistency was likely attributed to different BCG manufacturing periods in Mexico (69) . Additionally, this project uncovered novel deletions in BCG Mexico that shed light on its evolution. Two new RDs unique to BCG Mexico 1931 were discovered and named RDMex02 and RDMex03. RDMex02 encompasses a deletion in fadD23, a gene that has been implicated in sulfolipid production and association with macrophages (70) . RDMex03 was the largest deletion found in BCG Mexico 1931 and spanned four genes, one of which encodes the transcriptional regulator whiB6. It was also shown that BCG Mexico 1931 contains four unique SNPs, one of which occurs in ponA2, a gene that has been shown to be involved in sensitivity to heat shock and H 2 O 2 and survival of M. tuberculosis in mice (71) . Finally, whole-genome sequences for BCG Moreau (68) and BCG Korea (72) have also been reported, but comparative genomics studies to uncover novel mutations in these strains have yet to be completed.
With a number of whole-genome sequences of BCG strains now available, it is possible to begin a more indepth analysis of genetic polymorphisms that affect phenotypic traits of BCG, such as immunogenicity and virulence. A detailed whole-genome sequence comparison of the available BCG strains would shed light on the specific differences among BCG strains and further our understanding of the mechanisms of attenuation specific to each lineage. This would be useful in further delineating BCG strains into phenotypic/genetic categories that could mediate its protective efficacy.
CONCLUSION AND PERSPECTIVES: ATTENUATION OF VIRULENCE AND PROTECTIVE EFFICACY
While it is tempting to focus on the differences across BCG strains, there are certain unifying messages that emerge from the study of BCG. First, in spite of its multibillion-fold application, none of the BCG substrains have ever reverted to the virulent form of M. bovis. This finding suggests that during the attenuation process of BCG, multiple irreversible genetic changes have occurred that have permanently disabled BCG's ability to cause disease in the immune-competent host. This prediction has to a large degree been confirmed by genomic studies, suggesting that these vaccines can be given safely and can serve as the basis of new, engineered vaccines, whereas the alternative involves the de novo generation of new, attenuated strains of M. tuberculosis for which there is no track record of safety. The key pending question is not whether BCG vaccines are attenuated, but rather, whether certain strains are overattenuated and whether this would affect their ability to protect against TB.
Another message one can derive from the collective study of BCG strains is that unlike structural molecules (peptidoglycan, mycolic acids, etc.), secreted products (e.g., antigenic proteins, virulence lipids) are apparently dispensable under the conditions encountered during laboratory culture. It can be reasoned that these molecules play a particularly important role when the bacterium interacts with the host, whereas there is no selective pressure to maintain their production in the lab. In the case of antigens, BCG strains obtained after 1931 do not make ESAT-6, CFP-10, MPT64, MPT70, or MPB83; yet, despite the absence of five of the six immunodominant antigens of M. bovis, some of these BCG strains have provided protection against TB in multiple trials and case-control studies. A potential message is that the induction of antigen-specific immunity, which does occur with BCG vaccination, is not on the causal pathway of protection. Indeed, BCG has long been used in the treatment of bladder cancer, and a recent study found that BCG protects SCID mice against Candida albicans infection (74). These observations suggest (i) that the key biologic effects of BCG occur in inducing innate, rather than adaptive, immune responses, and (ii) that the immunologic effects are nonspecific. In the case of lipids, there is much more to be learned. BCG strains show differential production of triacylglycerols, methoxymycolic acids, and PDIMs/ PGLs. Whether reduction or loss of triacylglycerols and methoxymycolates affects protection is unknown. In contrast, emerging data indicate that the presence of PDIMs/PGLs may be important for BCG protection.
A challenge for future research on BCG will be to capitalize on the advances in descriptive and experimental genetics to determine how BCG vaccines differentially engage our immune system. While the historic literature on BCG protection revealed variability, and the contemporary literature on BCG genomics adds further complexity, we should not lose sight of the fact that BCG has provided proof-of-concept that TB is a vaccine-preventable illness. The secret to a TB vaccine is encoded in the genome of BCG.
